iCoat Medical

iCoat Medical AB, a pharmaceutical company based in Stockholm, Sweden develops multiple products targeting Ischemia Reperfusion injuries based on a patented technology platform.

TUM012, our lead product targets organ transplantation; kidney, heart, and liver, with several other indications being evaluated. The company is today operational in discovery and early phases of development, from idea to clinical trials, including invention and optimization of new drug candidates, evaluation of preclinical efficacy, safety, and confirmatory clinical trials.

iCoat Medical is also in the early stages of developing its own commercial organization.